Aberrant Regulation of the LIN28A/LIN28B and Let-7 Loop in Human Malignant Tumors and Its Effects on the Hallmarks of Cancer
Overview
Oncology
Affiliations
RNA binding proteins (RBPs) and microRNAs (miRNAs) are two of the most important post-transcriptional regulators of gene expression, and their aberrant expression contributes to the development of human malignancies. Let-7, one of the most well-known tumor suppressors, is frequently down-regulated in a variety of human cancers. The RBP LIN28A/LIN28B, a direct target of the let-7 family of miRNAs, is an inhibitor of let-7 biogenesis and is frequently up-regulated in cancers. Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors is reportedly involved in cancer development, contributing to cellular proliferation, cell death resistance, angiogenesis, metastasis, metabolism reprogramming, tumor-associated inflammation, genome instability, acquiring immortality and evading immune destruction. In this review, we summarized the mechanisms of LIN28A/LIN28B and let-7 loop aberrant regulation in human cancer and discussed the roles and potential mechanisms of the LIN28A/LIN28B and let-7 loop in regulating the hallmarks of cancer. The crosstalk between LIN28A/LIN28B and let-7 loop and certain oncogenes (such as MYC, RAS, PI3K/AKT, NF-κB and β-catenin) in regulating hallmarks of cancer has also been discussed.
Lin28/let-7 axis in breast cancer.
Shaik Syed Ali P, Ahmad M, Parveen K Mol Biol Rep. 2025; 52(1):311.
PMID: 40085362 DOI: 10.1007/s11033-025-10413-6.
RNA binding proteins (RBPs) on genetic stability and diseases.
Aborode A, Abass O, Nasiru S, Eigbobo M, Nefishatu S, Idowu A Glob Med Genet. 2025; 12(1):100032.
PMID: 39925443 PMC: 11803229. DOI: 10.1016/j.gmg.2024.100032.
Mohamed A, Nagah Amer N, Osama N, Hafez W, Abdelrahman Ali A, Shaheen M Noncoding RNA Res. 2025; 10():262-268.
PMID: 39844891 PMC: 11751402. DOI: 10.1016/j.ncrna.2024.12.003.
PHAX enhanced LIN28B-mediated PBX3 mRNA stability to promote esophageal cancer development.
Peng J, Lv L, Zhou Y, Wang X, Hu C Cancer Sci. 2024; 116(3):808-823.
PMID: 39668567 PMC: 11875786. DOI: 10.1111/cas.16420.
Targeting RBM39 suppresses tumor growth and sensitizes osteosarcoma cells to cisplatin.
Wang J, Zheng L, Chen W, Zhang X, Lv D, Zeng C Oncogene. 2024; 44(9):575-586.
PMID: 39633066 DOI: 10.1038/s41388-024-03242-7.